Immunomedics sinks after ASCO cancels presentation

Immunomedics Inc. (NASDAQ:IMMU) fell $0.78 (15%) to $4.52 on Friday after the American Society of Clinical Oncology withdrew an abstract and canceled a scheduled presentation of data from the Phase II portion of a Phase I/II study of sacituzumab govitecan ( IMMU-132) in patients with metastatic triple-negative breast cancer (TNBC). ...